Advice
Following a resubmission
gemcitabine (Gemzar®), in combination with paclitaxel, is accepted for restricted use within NHS Scotland for the treatment of patients with metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Gemcitabine in combination with paclitaxel modestly improves outcomes, compared to paclitaxel monotherapy, in those previously treated with an anthracycline.
For this indication gemcitabine is restricted to use by oncologists specialising in the treatment of breast cancer.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- gemcitabine 200mg and 1g powder for solution for infusion (Gemzar)
- SMC ID:
- 154/05
- Indication:
- Metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 11 December 2006